Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.47%0700.HK-6.31%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.76%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.70%0857.HK-1.46%UNH-10.21%1288.HK-1.78%PM-0.85%0005.HK-2.16%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.69%AUDUSD-1.58%AUDCAD-1.00%EURAUD+0.99%AUDCHF-0.99%GBPAUD+0.90%AUDNZD-0.87%NZDJPY-0.85%GBPJPY-0.80%EURJPY-0.73%NZDUSD-0.71%CADJPY-0.71%CHFJPY-0.70%GBPUSD-0.66%AUDSGD-0.63%USDCHF+0.62%EURUSD-0.60%USDCAD+0.59%AUDDKK-0.55%USDZAR+0.44%GBPTRY+0.41%USDMXN+0.41%USDNOK+0.35%USDTHB+0.35%AUDNOK-0.34%GBPHKD+0.32%NZDMXN+0.29%CHFNOK+0.29%GBPMXN-0.28%EURZAR+0.28%NOKJPY-0.28%USDSEK+0.24%GBPZAR+0.23%USDPLN+0.21%USDTRY+0.21%EURNOK+0.20%EURCNH-0.19%CHFSEK+0.18%EURHKD-0.17%USDILS+0.16%USDDKK+0.16%NZDCAD-0.14%USDJPY-0.14%GBPSGD-0.13%NZDCHF-0.13%PLNJPY-0.12%USDCNH-0.12%EURNZD+0.11%GBPCAD-0.09%EURSEK+0.09%EURSGD-0.08%EURGBP+0.07%USDSGD+0.07%EURPLN+0.05%GBPCHF-0.05%GBPNZD+0.05%EURCZK+0.04%USDCOP-0.04%NZDSGD-0.03%SGDJPY+0.02%CADCHF+0.02%EURCHF+0.02%USDHKD-0.02%EURCAD-0.01%CHFSGD0.00%EURDKK0.00%XPTUSD-1.21%XAGUSD-0.91%GAGUSD-0.90%W1-0.60%XAUUSD-0.59%GAUUSD-0.59%HG1-0.46%C1-0.40%XNGUSD-0.38%UKOIL+0.19%S1-0.19%COTTON-0.10%BTCUSD-3.68%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.67%ZECUSDT-7.18%XMRUSDT-2.30%DOGEUSD+55.95%LINKUSD-3.58%XLMUSD-3.94%BCHUSDT-3.64%LTCUSD+47.50%UNIUSD-3.23%SUIUSD-3.29%TONUSD+59.18%HBARUSDT-5.33%TAOUSDT-3.48%AAVEUSD-3.64%ONDOUSDT-5.58%ICPUSDT-2.22%DOTUSDT-4.03%WLDUSDT-3.94%ARBUSDT-5.88%ATOMUSDT-2.61%INJUSDT-8.05%STXUSDT-3.46%PYTHUSDT-1.30%TIAUSDT-3.37%FETUSDT-4.80%JUPUSDT+0.25%SEIUSDT-4.48%GRTUSDT-3.73%OPUSDT-3.90%IOTAUSDT-2.77%POLUSDT-2.01%WIFUSDT-2.98%AXSUSDT-3.20%EOSUSDT-4.46%IMXUSDT-4.36%FARTCOINUSDT-7.37%GALAUSDT-3.11%DYDXUSDT-3.12%ORDIUSDT-2.94%NOTUSDT-2.34%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.47%0700.HK-6.31%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.76%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.70%0857.HK-1.46%UNH-10.21%1288.HK-1.78%PM-0.85%0005.HK-2.16%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.69%AUDUSD-1.58%AUDCAD-1.00%EURAUD+0.99%AUDCHF-0.99%GBPAUD+0.90%AUDNZD-0.87%NZDJPY-0.85%GBPJPY-0.80%EURJPY-0.73%NZDUSD-0.71%CADJPY-0.71%CHFJPY-0.70%GBPUSD-0.66%AUDSGD-0.63%USDCHF+0.62%EURUSD-0.60%USDCAD+0.59%AUDDKK-0.55%USDZAR+0.44%GBPTRY+0.41%USDMXN+0.41%USDNOK+0.35%USDTHB+0.35%AUDNOK-0.34%GBPHKD+0.32%NZDMXN+0.29%CHFNOK+0.29%GBPMXN-0.28%EURZAR+0.28%NOKJPY-0.28%USDSEK+0.24%GBPZAR+0.23%USDPLN+0.21%USDTRY+0.21%EURNOK+0.20%EURCNH-0.19%CHFSEK+0.18%EURHKD-0.17%USDILS+0.16%USDDKK+0.16%NZDCAD-0.14%USDJPY-0.14%GBPSGD-0.13%NZDCHF-0.13%PLNJPY-0.12%USDCNH-0.12%EURNZD+0.11%GBPCAD-0.09%EURSEK+0.09%EURSGD-0.08%EURGBP+0.07%USDSGD+0.07%EURPLN+0.05%GBPCHF-0.05%GBPNZD+0.05%EURCZK+0.04%USDCOP-0.04%NZDSGD-0.03%SGDJPY+0.02%CADCHF+0.02%EURCHF+0.02%USDHKD-0.02%EURCAD-0.01%CHFSGD0.00%EURDKK0.00%XPTUSD-1.21%XAGUSD-0.91%GAGUSD-0.90%W1-0.60%XAUUSD-0.59%GAUUSD-0.59%HG1-0.46%C1-0.40%XNGUSD-0.38%UKOIL+0.19%S1-0.19%COTTON-0.10%BTCUSD-3.68%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.67%ZECUSDT-7.18%XMRUSDT-2.30%DOGEUSD+55.95%LINKUSD-3.58%XLMUSD-3.94%BCHUSDT-3.64%LTCUSD+47.50%UNIUSD-3.23%SUIUSD-3.29%TONUSD+59.18%HBARUSDT-5.33%TAOUSDT-3.48%AAVEUSD-3.64%ONDOUSDT-5.58%ICPUSDT-2.22%DOTUSDT-4.03%WLDUSDT-3.94%ARBUSDT-5.88%ATOMUSDT-2.61%INJUSDT-8.05%STXUSDT-3.46%PYTHUSDT-1.30%TIAUSDT-3.37%FETUSDT-4.80%JUPUSDT+0.25%SEIUSDT-4.48%GRTUSDT-3.73%OPUSDT-3.90%IOTAUSDT-2.77%POLUSDT-2.01%WIFUSDT-2.98%AXSUSDT-3.20%EOSUSDT-4.46%IMXUSDT-4.36%FARTCOINUSDT-7.37%GALAUSDT-3.11%DYDXUSDT-3.12%ORDIUSDT-2.94%NOTUSDT-2.34%RONINUSDT-2.92%
EX

Exelixis, Inc. (EXEL)

NASDAQ • Healthcare

$68.29
-$0.2 (-0.3%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$68.08
Day Range$67.79 - $69.47
Avg. Volume (3M)2.8M
Market Cap$17.1B
P/E Ratio19.8
52 Week Range
$39.71$73.69
Next EarningsIn 82 daysFeb 9, 2027

Metrics Over Time

Where the Money Goes

Q4 2026
Revenueeverything earned$658.6M100%
Gross Profitminus cost of goods$632.4M96%
Operating Incomeminus R&D and overhead$268.4M41%
Net Incomeminus taxes and the rest$218M33%

In plain terms: out of every $100 in revenue, Exelixis, Inc. keeps $33 as net profit.

Fundamentals & Financials

Revenue (TTM)
$2.4B
Net Income (TTM)
$885.1M
EPS (TTM)
$3.45
ROA (TTM)
35.22%
Current Ratio
3.21

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+13.7%Q2 2026$0.87
+6.7%Q3 2026$0.91
+6.0%Q4 2026$0.94
Next

Feb 9

in 82 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +6.0%

Exelixis beat expectations on both the top and bottom line in the third fiscal quarter of 2026, reported October 29, 2026, with adjusted EPS of $0.94 topping the $0.89 estimate (+6%) and revenue of $658.7 million topping the $646.5 million estimate (+1.9%). Revenue rose 10.2% to about $658.7 million from roughly $597.8 million a year ago, with the U.S. business contributing the majority as U.S. revenue increased 11.5% to about $609.1 million, while Europe revenue edged down 1.5% to roughly $44.3 million and Japan revenue fell 16.3% to about $5.3 million. Profitability tracked higher year over year as net income increased 12.7% to about $218.1 million, up from roughly $193.6 million a year earlier, alongside GAAP operating income of about $268.4 million. On the bottom line, adjusted EPS rose 20.5% from $0.78 a year ago. The quarter generated operating cash flow of about $280.0 million, and the company repurchased roughly $250.0 million of stock.

View full earnings history

About Exelixis, Inc.

Exelixis, Inc. is a NASDAQ-listed biotechnology company that develops and commercializes cancer medicines and other therapies, generating $2.3 billion in FY2025 revenue. Its marketed portfolio centers on CABOMETYX tablets, COMETRIQ capsules, and COTELLIC for oncology, alongside MINNEBRO for hypertension, with commercial activity in the United States and Japan.

Name
Exelixis, Inc.
CEO
Michael Morrissey
Industry
Healthcare
Year Founded
1994
Employees
1,077

Today's Snapshot

AI-generated

EXEL closed slightly lower at 68.29, while its sector was weaker. Trading was lighter than usual, with volume about two-thirds of its usual level. Exelixis discussed zanza, an experimental cancer drug, and its seven pivotal trials at a healthcare conference.

Trading Volume

Below 10d avg (2.9M)

1.8M

vs S&P 500 Today

Inline with Market

-0.05%

Updated: November 18, 2026 at 21:24 UTC

Technical Indicators

4 Buy3 Neutral1 Sell
EXEL trades around $68.29 and presents a constructive technical picture with price above most medium- and long-term moving averages while hovering near short-term averages, suggesting underlying strength. ADX close to 34.9 implies a well-defined trend and OBV indicates accumulation, although momentum indicators are modest with RSI in the mid-50s and MACD slightly positive. Volatility is moderate with an ATR near 3.2%, keeping moves orderly. The classic pivot is just below the market and does not negate the prevailing bullish structure. Technical takeaway: Buy.
All signals
  • EMA (5 indicators)$54.06 - $68.88
    Buy
  • RSI (14)55.01
    Neutral
  • Stochastic %K (14, 3, 3)31.16
    Neutral
  • MACD Level (12, 26)1.76
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.